Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

L-2-Aminobutyric acid is a non-proteinogenic amino acid.1 It inhibits LPS-induced nitric oxide (NO) production in, and reduces the bactericidal activity of, isolated mouse bone marrow-derived macrophages (BMDMs) when used at concentrations of 0.1 and 1 mM. L-2-Aminobutyric acid (75 mg/kg) increases survival in mouse models of sepsis induced by LPS or cecum ligation and puncture and decreases disease severity in a mouse model of inflammatory bowel disease (IBD) induced by dextran sodium sulfate (DSS; Item No. 23250). Serum levels of L-2-aminobutyric acid are increased in patients with COVID-19 and increased serum levels are associated with higher overall survival in patients with head and neck cancer.2,3 It has been used in the synthesis of several compounds, including the antiepileptic levetiracetam (Item No. 9001820) and antimycobacterial agent ethambutol (Item No. 23713).4
WARNING This product is not for human or veterinary use.
1. α-
2. The serum amino acid profile in COVID-
3. Prognostic role of serum amino acids in head and neck cancer. Dis. Markers 2291759 (2020).
4. Expanding metabolism for total biosynthesis of the nonnatural amino acid L-